HC Wainwright Research Analysts Lower Earnings Estimates for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at HC Wainwright cut their Q1 2024 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a report issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.28) per share for the quarter, down from their prior forecast of ($0.27). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.04) EPS and FY2025 earnings at ($1.09) EPS.

Separately, Benchmark restated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Down 1.3 %

Shares of RVPH opened at $3.02 on Wednesday. The firm’s fifty day moving average is $3.57 and its two-hundred day moving average is $4.10. The stock has a market cap of $84.32 million, a PE ratio of -1.84 and a beta of -0.02. Reviva Pharmaceuticals has a 52-week low of $2.67 and a 52-week high of $9.25.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Armistice Capital LLC increased its position in shares of Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after purchasing an additional 1,164,000 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Reviva Pharmaceuticals during the fourth quarter worth about $72,000. Finally, EMC Capital Management increased its position in shares of Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after acquiring an additional 115,028 shares during the last quarter. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.